PURPOSE: The glycoprotein macrophage migration inhibitory factor (MIF) is a cytokine that has been shown to promote tumor progression and tumor immune escape in ovarian cancer. The present study investigates MIF in uterine cervical cancer. METHODS: Eighty surgical biopsies (32 cervical dysplasias, 23 in situ carcinomas and 25 invasive carcinomas) of uterine cervical tissue were evaluated immunohistochemically for MIF expression. In uterine cervical cancer cell lines SiHa and CaSki and their respective supernatants, MIF protein expression was analyzed by Western blotting, enzyme-linked immunosorbent assay (ELISA) and reverse transcriptase polymerase chain reaction (RT-PCR). RESULTS: Immunohistochemical analysis shows that MIF is clearly overexpressed on the protein level in invasive cervical cancer compared to cervical dysplasias. MIF overexpression was confirmed by RT-PCR in surgical biopsies of invasive cervical cancer. Western blotting reveals that the MIF protein is overexpressed in SiHA und CaSki cervical cancer cell lines, whereas the ELISA reveals that cervical cancer cells secrete MIF. CONCLUSIONS: MIF has been shown to promote tumor immune escape mechanisms in other cancer entities, which makes it an interesting target for cancer therapy, given the known significance of immune mechanisms for uterine cervical cancer. The overexpression of MIF on the protein and mRNA level, as well as its secretion by cervical cancer cells points to a critical role of the protein for the pathogenesis of uterine cervical cancer.
PURPOSE: The glycoprotein macrophage migration inhibitory factor (MIF) is a cytokine that has been shown to promote tumor progression and tumor immune escape in ovarian cancer. The present study investigates MIF in uterine cervical cancer. METHODS: Eighty surgical biopsies (32 cervical dysplasias, 23 in situ carcinomas and 25 invasive carcinomas) of uterine cervical tissue were evaluated immunohistochemically for MIF expression. In uterine cervical cancer cell lines SiHa and CaSki and their respective supernatants, MIF protein expression was analyzed by Western blotting, enzyme-linked immunosorbent assay (ELISA) and reverse transcriptase polymerase chain reaction (RT-PCR). RESULTS: Immunohistochemical analysis shows that MIF is clearly overexpressed on the protein level in invasive cervical cancer compared to cervical dysplasias. MIF overexpression was confirmed by RT-PCR in surgical biopsies of invasive cervical cancer. Western blotting reveals that the MIF protein is overexpressed in SiHA und CaSki cervical cancer cell lines, whereas the ELISA reveals that cervical cancer cells secrete MIF. CONCLUSIONS:MIF has been shown to promote tumor immune escape mechanisms in other cancer entities, which makes it an interesting target for cancer therapy, given the known significance of immune mechanisms for uterine cervical cancer. The overexpression of MIF on the protein and mRNA level, as well as its secretion by cervical cancer cells points to a critical role of the protein for the pathogenesis of uterine cervical cancer.
Authors: H Lue; M Thiele; J Franz; E Dahl; S Speckgens; L Leng; G Fingerle-Rowson; R Bucala; B Lüscher; J Bernhagen Journal: Oncogene Date: 2007-02-19 Impact factor: 9.867
Authors: G Fingerle-Rowson; O Petrenko; C N Metz; T G Forsthuber; R Mitchell; R Huss; U Moll; W Müller; R Bucala Journal: Proc Natl Acad Sci U S A Date: 2003-07-23 Impact factor: 11.205
Authors: K L Meyer-Siegler; P L Vera; K A Iczkowski; C Bifulco; A Lee; P K Gregersen; L Leng; R Bucala Journal: Genes Immun Date: 2007-08-30 Impact factor: 2.676
Authors: Mathias Krockenberger; Yvonne Dombrowski; Claudia Weidler; Monika Ossadnik; Arnd Hönig; Sebastian Häusler; Heike Voigt; Jürgen C Becker; Lin Leng; Alexander Steinle; Michael Weller; Richard Bucala; Johannes Dietl; Jörg Wischhusen Journal: J Immunol Date: 2008-06-01 Impact factor: 5.422
Authors: Inbal Binsky; Michal Haran; Diana Starlets; Yael Gore; Frida Lantner; Nurit Harpaz; Lin Leng; David M Goldenberg; Lev Shvidel; Alain Berrebi; Richard Bucala; Idit Shachar Journal: Proc Natl Acad Sci U S A Date: 2007-08-08 Impact factor: 11.205
Authors: Jonathan M Wilson; P Louise Coletta; Richard J Cuthbert; Nigel Scott; Kenneth MacLennan; Gillian Hawcroft; Lin Leng; Jodi B Lubetsky; Kai K Jin; Elias Lolis; Francisco Medina; Jose A Brieva; Richard Poulsom; Alexander F Markham; Richard Bucala; Mark A Hull Journal: Gastroenterology Date: 2005-11 Impact factor: 22.682
Authors: Nadège Kindt; Julie Preillon; Herbert Kaltner; Hans-Joachim Gabius; Dominique Chevalier; Alexandra Rodriguez; Bryon D Johnson; Véronique Megalizzi; Christine Decaestecker; Guy Laurent; Sven Saussez Journal: J Cancer Res Clin Oncol Date: 2013-01-25 Impact factor: 4.553
Authors: Nadège Kindt; Jérôme R Lechien; Denis Nonclercq; Guy Laurent; Sven Saussez Journal: J Cancer Res Clin Oncol Date: 2014-03-25 Impact factor: 4.553